Get the Stockscreener App
0.2752
4.80%
0.0126
After Hours:
.28
0.0048
+1.74%
Medicus Pharma Ltd stock is traded at $0.2752, with a volume of 4.13M.
It is up +4.80% in the last 24 hours and down -38.34% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.2626
Open:
$0.278
24h Volume:
4.13M
Relative Volume:
2.15
Market Cap:
$15.59M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.1546
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-25.62%
1M Performance:
-38.34%
6M Performance:
-76.87%
1Y Performance:
-88.81%
1-Day Range:
$0.263
$0.285
1-Week Range:
$0.2511
$0.379
52-Week Range:
$0.25
$3.05
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.2752 | 18.03M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,148.52 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.42 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
251.06 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.22 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.14 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome - Proactive financial news
Small cap wrap: Nextsource Materials, First Phosphate, Medicus Pharma, Nextech3D.ai… - Proactive financial news
FDA clears Medicus Pharma to start Phase 2b tri... - Pluang
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome - Yahoo Finance
FDA clears Medicus Pharma to start pivotal SkinJect trial for Gorlin Syndrome skin cancer treatment - Pluang
FDA clears Medicus Pharma Gorlin Syndrome study to proceed - Investing.com
Medicus Pharma Receives FDA “Study May Proceed” Letter for - GlobeNewswire
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCXW - TradingView
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings - Moomoo
MDCX|Medicus Pharma Ltd|Price:0.370|Chg%:-0.014 - TradingKey
TradingKey - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCX - TradingView
MDCX|Medicus Pharma Ltd|Price:0.303|Chg%:-0.015 - TradingKey
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review - MyChesCo
Medicus Pharma Ltd. (MDCX) Declines 7.39% as Stock Approaches Key Support at $0.36WMA Signal - dars.gov.et
Medicus Pharma CEO details Teverelix progress – ICYMI - Proactive financial news
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds - MyChesCo
Medicus Pharma advances Phase 2 study following FDA and IRB feedback - Proactive financial news
Medicus Pharma (MDCX) Receives FDA Feedback for Clinical Study - GuruFocus
Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention - Bitget
Medicus Pharma redesigns Phase 2 trial for 126 patients - grafa.com
Medicus Pharma receives FDA feedback for optimized Phase 2 study By Investing.com - Investing.com Nigeria
Medicus Pharma receives FDA feedback for optimized Phase 2 study - Investing.com
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention - The Manila Times
Medicus Pharma Receives Positive FDA Feedback and Central - GlobeNewswire
Medicus Pharma (MDCX) Stock Forum and Discussion - Moomoo
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval - Proactive financial news
Medicus Pharma Expects About 126 Patients in Redesigned Teverelix Study - Stock Titan
Medicus Pharma on Bloomberg World - Independent Mail
Number of shareholders of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Number of shareholders of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Medicus Pharma Ltd. (MDCX) Slips 3.5% as Stock Nears Critical Support LevelIndex Put Call - DonanımHaber
Enterprise value to revenue forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - MPNnow.com
Enterprise value to EBIT forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Price to sales forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - The Poughkeepsie Journal
MDCXMedicus Pharma Ltd Revenue Breakdown - Finviz
MDCX Q1 2026 Earnings: Wider-than-expected loss as clinical programs advanceEarnings Outlook Update - dars.gov.et
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group - Voice of Alexandria
Medicus Pharma (MDCX) Stock Analysis Report | Financials & Insights - Benzinga España
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):